Regeneron Pharmaceuticals Inc REGN

NASDAQ US Health Care Biotechnology

$762.63 ▲ +3.29% (+$24.29)

Index member: S&P 500

⬆️ Above Yest. High

Open $726.69

Prev Close $738.34

Day Range $724.79 – $764.75

52W Range $541.00 – $821.11

Market Cap $79.94B

P/E (TTM) 17.49

Beta 0.19

Div Yield 0.51%

EPS (TTM) $41.03

📋 Company Profile

Industry	Biotechnology
Sector	Health Care
Country	US
Exchange	NASDAQ NMS - GLOBAL MARKET
Currency	USD
IPO Date	1991-04-02
Shares Out.	104,840,000
Website	regeneron.com/ ↗
Phone	17813705000
Employees	15,410
Revenue	$4.29B
Gross Profit	$3.71B
Net Income	$1.30B
Free Cash Flow	$3.76B
Total Assets	$41.73B
Total Liabilities	$10.02B
Equity	$31.71B

About Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; Kevzara in rheumatoid arthritis; and Lynozyfic for multiple myeloma. Regeneron has multiple partnerships and collaboration agreements, with Sanofi (Dupixent, others) and Bayer (Eylea) as its largest partners.

Regeneron Pharmaceuticals Inc is a publicly traded company under the ticker symbol REGN on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.